Could a new treatment developed by the US pharmaceutical company Lilley mean the beginning of the end of Alzheimer's?Could we even cure the disease some day?These are the types of headlines and questions swirling around after news of a new drug, called donanemab, showed promising results in phase-3 trials at slowing down the decline in cognitive functions and reducing the deterioration in the ability to undertake daily tasks independently.
#years #information #significantly #participants #press-release #independently #effectiveness #important-role #private-companies
[
add
]
[
|
|
...
]